FJFrances E. Jensen

Frances E. Jensen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Frances E. Jensen has a total of 111 co-authors. Here are the top co-authors by number of shared publications:

  • Delia M. Talos

    Department of Neurology, Perelman School of Medicine, University of Pennsylvania; Philadelphia, PA 19104, USA

    9 shared publications
  • Hongyu Sun

    Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Department of Neuroscience, Carleton University, Ottawa, ON K1S 5B6, Canada

    6 shared publications
  • Peter M. Klein

    Department of Neurosurgery, Stanford University, Stanford, USA

    4 shared publications
  • Delia M. Talos

    Department of Neurology, Boston Children's Hospital, Boston, MA 02115, USA Harvard Medical School, Boston, MA 02115, USA Current address: Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA

    3 shared publications
  • Jocelyn J. Lippman-Bell

    Perelman School of Medicine, University of Pennsylvania, Department of Neurology, Philadelphia, PA 19104, United States; Boston Children's Hospital, Department of Neurology, Boston, MA 02115, United States; Philadelphia College of Osteopathic Medicine, Department of Biomedical Sciences, Philadelphia, PA 19131, United States

    3 shared publications
  • Aaron J Barbour

    Department of Neurology, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA 19104 , USA

    2 shared publications

Latest Publications

  • Open Access

    Seizures drive tau propagation in a tauopathy mouse model

    by Aaron J. Barbour, Keegan Hoag, Virginia M.Y. Lee, Delia M. Talos, Frances E. Jensen

    A bidirectional relationship between seizures and neurodegenerative disease has been established with neurodegenerative pathology found in late-onset epilepsy patients, increased risk of seizures in tauopathies, and accelerated Alzheimer’s disease progression in patients with epileptiform activity. Tau pathology spreads between interconnected neuronal networks, driving disease progression. We hypothesized that seizures would promote tau propagation throughout the brain in a tauopathy mouse model. To explore the brain-wide relationship between tau pathology and seizure activity, we crossed the T40PL-GFP mouse, which contains a pathogenic MAPT mutation tagged with GFP, with targeted recombination in active population (TRAP; T40PL-TRAP) mice to label all seizure activated neurons with tdTomato. We triggered tau propagation in these mice with intracerebral seeding of human AD brain-derived tau lysate and induced seizures with pentylenetetrazol (PTZ) kindling. With light sheet microscopy, we imaged and mapped tau-GFP and tdT levels throughout whole brain. We found that PTZ induced seizures worsened tau pathology in brain regions with increased tdT levels, including the hippocampus and cortex, and in the fiber tracts in T40PL-TRAP mice. We also found that seizure-activated (tdT+) neurons were more likely to develop somatic tau pathology compared to the surrounding (tdT-) populations. Overall, these data demonstrate that seizures can enhance tau pathology propagation.

  • Open Access

    Temporal and cell-specific changes to cellular iron sequestration and lipid peroxidation in a murine model of neonatal hypoxic-ischemic brain injury

    by Joseph Vithayathil, Anjali Shankar, Ginger L Milne, Frances E Jensen, Delia M Talos, Joshua L Dunaief

    Background: Iron accumulation and lipid peroxidation are pathophysiologic mechanisms that drive neonatal hypoxic-ischemic (HI) brain injury. Characterization of spatiotemporal changes in these processes will help elucidate their role in ischemic neuronal injury as an initial step towards developing targeted interventions. Methods: HI was induced in post-natal day 9 mice using the modified-Vannucci model. Hippocampal tissue from ipsilateral HI exposed, contralateral hypoxia exposed and sham animals was collected at 6h, 24h, 72h and 7d post-HI. Tissue was subsequently evaluated for markers of cell death (TUNEL), intracellular iron changes (FerroOrange, fluorescent in situ and immunofluorescence), and lipid peroxidation (real time PCR, Gpx4 immunofluorescence and mass spectrometry). Mass spectrometry measured isoprostanes (15-F 2t -IsoP) and neuroprostanes (4-F 4t -NP) as lipid peroxidation markers of arachidonic (ARA) and docosahexaenoic acid (DHA), respectively. Results: Compared to sham, the HI hippocampus showed increased intracellular labile iron levels that was maximal at 6h post-HI with subsequent elevation in only neuroprostanes at 24h post-HI. TUNEL labeling peaked at 24h post-HI. At 72h, labile iron levels and lipid peroxidation declined corresponding with peak infiltration of ferritin positive microglia/macrophages and the start of TUNEL staining decline. In addition, surviving neurons had increased expression of Gpx4 peaking at 72h post-HI that normalized by 7d post-HI. Conclusions: These findings suggest that following HI, an acute increase in labile iron and DHA peroxidation are correlated with markers of cell death that peak at 24h post-HI. Microglial/macrophage iron sequestration and neuronal antioxidant responses may ameliorate further injury and represent targets for neuroprotective therapies.


  • Open Access

    Hyperactive neuronal networks enhance tau spread in an Alzheimer’s disease mouse model

    by Aaron J. Barbour, Keegan Hoag, Eli J. Cornblath, Abigail Chavez, Alfredo Lucas, Xiaofan Li, Sydney Zebrowitz, Chloe Hassman, Edward B. Lee, Kathryn A. Davis, et al.

    Pathological tau spreads via neuronal connections in Alzheimer’s disease (AD). Given the high incidence and deleterious consequences of epileptiform activity in AD, we hypothesized that neuronal hyperactivity and seizures exacerbate tau spread. To examine the impacts of brain-wide network and population hyperactivity on tau spread, we created a novel mouse model involving the cross of targeted recombination in active populations (TRAP) and the 5 times familial AD mice (5X-TRAP) that allows for the permanent labelling of seizure-activated neurons. To explore the effects of seizures on tau spread, we injected these mice with human AD brain-derived tau to induce pathological tau spread, and induced seizures with pentylenetetrazol (PTZ) kindling. Brain mapping revealed that seizures increased tau spread in 5X-TRAP mice, which correlated extensively with memory deficits in PTZ kindled 5X-TRAP mice. Using computational models, we found data supportive of increased anterograde tau spread in 5X-TRAP mice and that regional neuronal activity levels were predictive of tau pathology. On a cellular level, we found that hyperactive neurons drive elevated tau propagation in 5X-TRAP mice. We also found corroborating evidence of increased tau spread in AD patients with a seizure history compared to those without. Our study identifies neuronal hyperactivity and seizures as key, targetable factors underlying AD progression.


  • Top Cited Papers

    Seizures exacerbate excitatory: inhibitory imbalance in Alzheimer’s disease and 5XFAD mice

    by Aaron J Barbour, Sarah Gourmaud, Eunjoo Lancaster, Xiaofan Li, David A Stewart, Keegan F Hoag, David J Irwin, Delia M Talos, Frances E Jensen

    Approximately 22% of Alzheimer’s disease (AD) patients suffer from seizures, and the co-occurrence of seizures and epileptiform activity exacerbates AD pathology and related cognitive deficits, suggesting that seizures may be a targetable component of AD progression. Given that alterations in neuronal excitatory:inhibitory (E:I) balance occur in epilepsy, we hypothesized that decreased markers of inhibition relative to those of excitation would be present in AD patients. We similarly hypothesized that in five times familial AD (5XFAD) mice, the E:I imbalance would progress from an early stage (prodromal) to later symptomatic stages, and be further exacerbated by pentylenetetrazol (PTZ) kindling. Post-mortem AD temporal cortical tissue from patients with or without seizure history were examined for changes in several markers of E:I balance, including levels of the inhibitory GABAA receptor, the sodium potassium chloride cotransporter 1 (NKCC1) and potassium chloride cotransporter 2 (KCC2), and the excitatory NMDA and AMPA type glutamate receptors. We performed patch clamp electrophysiological recordings from CA1 neurons in hippocampal slices and examined the same markers of E:I balance in prodromal 5XFAD mice. We next examined 5XFAD mice at chronic stages, after PTZ or control protocols, and in response to chronic mTORC1 inhibitor rapamycin, administered following kindled seizures, for markers of E:I balance. We found that AD patients with comorbid seizures had worsened cognitive and functional scores and had decreased GABAA receptor subunit expression, and increased NKCC1/KCC2 ratios, indicative of depolarizing GABA responses. Patch clamp recordings of prodromal 5XFAD CA1 neurons showed increased intrinsic excitability, along with decreased GABAergic inhibitory transmission and altered glutamatergic neurotransmission, indicating that E:I imbalance may occur in early disease stages. Furthermore, seizure induction in prodromal 5XFAD mice led to later dysregulation of NKCC1/KCC2 and a reduction in GluA2 AMPA glutamate receptor subunit expression, indicative of depolarizing GABA receptors and calcium permeable AMPA receptors. Finally, we found that chronic treatment with the mTORC1 inhibitor, rapamycin, at doses we have previously shown to attenuate seizure-induced β-amyloid pathology and cognitive deficits, could also reverse elevations to NKCC1/KCC2 ratio in these mice. Our data demonstrate novel mechanisms of interaction between AD and epilepsy and indicate that targeting E:I balance, potentially with FDA-approved mTOR inhibitors, hold therapeutic promise for AD patients with a seizure history.


  • Open Access

    Reversible synaptic adaptations in a subpopulation of murine hippocampal neurons following early-life seizures

    by Bo Xing, Aaron J. Barbour, Joseph Vithayathil, Xiaofan Li, Sierra Dutko, Jessica Fawcett-Patel, Eunjoo Lancaster, Delia M. Talos, Frances E. Jensen

    Early-life seizures (ELSs) can cause permanent cognitive deficits and network hyperexcitability, but it is unclear whether ELSs induce persistent changes in specific neuronal populations and whether these changes can be targeted to mitigate network dysfunction. We used the targeted recombination of activated populations (TRAP) approach to genetically label neurons activated by kainate-induced ELSs in immature mice. The ELS-TRAPed neurons were mainly found in hippocampal CA1, remained uniquely susceptible to reactivation by later-life seizures, and displayed sustained enhancement in α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor–mediated (AMPAR-mediated) excitatory synaptic transmission and inward rectification. ELS-TRAPed neurons, but not non-TRAPed surrounding neurons, exhibited enduring decreases in Gria2 mRNA, responsible for encoding the GluA2 subunit of the AMPARs. This was paralleled by decreased synaptic GluA2 protein expression and heightened phosphorylated GluA2 at Ser880 in dendrites, indicative of GluA2 internalization. Consistent with increased GluA2-lacking AMPARs, ELS-TRAPed neurons showed premature silent synapse depletion, impaired long-term potentiation, and impaired long-term depression. In vivo postseizure treatment with IEM-1460, an inhibitor of GluA2-lacking AMPARs, markedly mitigated ELS-induced changes in TRAPed neurons. These findings show that enduring modifications of AMPARs occur in a subpopulation of ELS-activated neurons, contributing to synaptic dysplasticity and network hyperexcitability, but are reversible with early IEM-1460 intervention.


  • Anti-seizure efficacy of perampanel in two established rodent models of early-life epilepsy

    by Nicholas S. Roberts, Marcus J. Handy, Yoshimasa Ito, Keisuke Hashimoto, Frances E. Jensen, Delia M. Talos


  • In Memoriam: Arthur Knight Asbury, MD (1928–2022)

    by Mark J. Brown, Frances E. Jensen, Howard Hurtig

  • Open Access

    Optical Redox Imaging of Ex Vivo Hippocampal Tissue Reveals Age-Dependent Alterations in the 5XFAD Mouse Model of Alzheimer’s Disease

    by He N. Xu, Sarah Gourmaud, Allison Podsednik, Xiaofan Li, Huaqing Zhao, Frances E. Jensen, Delia M. Talos, Lin Z. Li

    A substantial decline in nicotinamide adenine dinucleotide (NAD) has been reported in brain tissue homogenates or neurons isolated from Alzheimer’s disease (AD) models. NAD, together with flavin adenine dinucleotide (FAD), critically supports energy metabolism and maintains mitochondrial redox homeostasis. Optical redox imaging (ORI) of the intrinsic fluorescence of reduced NAD (NADH) and oxidized FAD yields cellular redox and metabolic information and provides biomarkers for a variety of pathological conditions. However, its utility in AD has not been characterized at the tissue level. We performed ex vivo ORI of freshly dissected hippocampi from a well-characterized AD mouse model with five familial Alzheimer’s disease mutations (5XFAD) and wild type (WT) control littermates at various ages. We found (1) a significant increase in the redox ratio with age in the hippocampi of both the WT control and the 5XFAD model, with a more prominent redox shift in the AD hippocampi; (2) a higher NADH in the 5XFAD versus WT hippocampi at the pre-symptomatic age of 2 months; and (3) a negative correlation between NADH and Aβ42 level, a positive correlation between Fp and Aβ42 level, and a positive correlation between redox ratio and Aβ42 level in the AD hippocampi. These findings suggest that the ORI can be further optimized to conveniently study the metabolism of freshly dissected brain tissues in animal models and identify early AD biomarkers.


  • Open Access

    The role of mTORC1 activation in seizure-induced exacerbation of Alzheimer's disease

    by Sarah Gourmaud, David A Stewart, David J Irwin, Nicholas Roberts, Aaron J Barbour, Grace Eberwine, William T O’bRien, Robert Vassar, Delia M Talos, Frances E Jensen

    The risk of seizures is 10-fold higher in patients with Alzheimer’s disease than the general population, yet the mechanisms underlying this susceptibility and the effects of these seizures are poorly understood. To elucidate the proposed bidirectional relationship between Alzheimer’s disease and seizures, we studied human brain samples (n = 34) from patients with Alzheimer’s disease and found that those with a history of seizures (n = 14) had increased amyloid-β and tau pathology, with upregulation of the mechanistic target of rapamycin (mTOR) pathway, compared with patients without a known history of seizures (n = 20). To establish whether seizures accelerate the progression of Alzheimer’s disease, we induced chronic hyperexcitability in the five times familial Alzheimer’s disease mouse model by kindling with the chemoconvulsant pentylenetetrazol and observed that the mouse model exhibited more severe seizures than the wild-type. Furthermore, kindled seizures exacerbated later cognitive impairment, Alzheimer’s disease neuropathology and mTOR complex 1 activation. Finally, we demonstrated that the administration of the mTOR inhibitor rapamycin following kindled seizures rescued enhanced remote and long-term memory deficits associated with earlier kindling and prevented seizure-induced increases in Alzheimer’s disease neuropathology. These data demonstrated an important link between chronic hyperexcitability and progressive Alzheimer’s disease pathology and suggest a mechanism whereby rapamycin may serve as an adjunct therapy to attenuate progression of the disease.


  • Altered hippocampal dendritic spine maturation after hypoxia-induced seizures in neonatal rats

    by Jocelyn J. Lippman-Bell, Marcus Handy, Cassidy G. Nieder, Mollie Getzfread, Frances E. Jensen